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integrative phenotyping of 
glycemic responders upon clinical 
weight loss using multi-omics
Armand Valsesia1 ✉, Anirikh chakrabarti1, Jörg Hager1, Dominique Langin2,3,4, 
Wim H. M. Saris5, Arne Astrup6, ellen e. Blaak5, nathalie Viguerie2 & Mojgan Masoodi1,7 ✉
Weight loss aims to improve glycemic control in obese but strong variability is observed. Using a multi-
omics approach, we investigated differences between 174 responders and 201 non-responders, that had 
lost >8% body weight following a low-caloric diet (LCD, 800 kcal/d for 8 weeks). The two groups were 
comparable at baseline for body composition, glycemic control, adipose tissue transcriptomics and 
plasma ketone bodies. But they differed significantly in their response to LCD, including improvements 
in visceral fat, overall insulin resistance (IR) and tissue-specific IR. Transcriptomics analyses found 
down-regulation in key lipogenic genes (e.g. SCD, ELOVL5) in responders relative to non-responders; 
metabolomics showed increase in ketone bodies; while proteomics revealed differences in lipoproteins. 
Findings were consistent between genders; with women displaying smaller improvements owing 
to a better baseline metabolic condition. Integrative analyses identified a plasma omics model that 
was able to predict non-responders with strong performance (on a testing dataset, the Receiving 
Operating Curve Area Under the Curve (ROC AUC) was 75% with 95% Confidence Intervals (CI) [67%, 
83%]). This model was based on baseline parameters without the need for intrusive measurements and 
outperformed clinical models (p = 0.00075, with a +14% difference on the ROC AUCs). Our approach 
document differences between responders and non-responders, with strong contributions from liver 
and adipose tissues. Differences may be due to de novo lipogenesis, keto-metabolism and lipoprotein 
metabolism. These findings are useful for clinical practice to better characterize non-responders both 
prior and during weight loss.
Obesity is a major risk factor for a number of co-morbidities including cardiovascular disease, dyslipidemia, 
hypertension, insulin resistance, type-2 diabetes (T2D), non-alcoholic fatty liver (NAFLD) and cancer1–4.
Weight loss can be achieved with energy-restricted dietary interventions and generally leads to improved gly-
cemic control5–7. Recent evidence shows that low-caloric diet interventions can enable T2D remission and have 
superior efficacy compared to routine primary care7. Nevertheless, large inter-individual variability is observed in 
LCD studies regarding the capacity in particular to maintain weight loss8–10. A key outcome of caloric restriction, 
apart from desired reduction in fat mass, is the effect on adipose tissue function9,11. Adipose tissue is impor-
tant in energy homeostasis and responding dynamically to caloric intake12–14. This is, partly due to lipolysis rate 
and adipose tissue triacylglycerol (TAG) turnover in response to caloric intake. The adipose tissue expandabil-
ity hypothesis suggests that insulin resistance is caused by lipotoxicity resulting from adipose tissue inability to 
expand further, leading to ectopic deposition of lipids in non-adipose organs such as liver, muscle and pancreatic 
beta cells15. Comprehensive assessment of circulating lipid pattern could be a useful marker of insulin resistance 
and it may reflect adipose tissue dysfunction and hepatic de novo lipogenesis.
We were the first to report that even within subjects achieving significant weight loss (>8% of initial body 
mass), only a fraction would achieve significant glycemic improvements16. Specifically, subjects could be 
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classified as glycemic responders and non-responders based on a lipid signature reflecting changes following 
LCD. Interestingly, these subjects only appeared to differ in their response to LCD whereas they had similar 
baseline body weight and glycemic variables. However, the underlying mechanism and physiological changes are 
not fully understood.
Considering the complexity of defining mechanism of action in a clinical cohort, we thus sought to perform a 
deeper characterization of these subjects using additional omics datasets including metabolomics and proteomics 
(>1,100 proteins) of plasma, together with transcriptomics (RNA-sequencing) of adipose Tissue (AT) biopsies. 
We also aimed to investigate further the tissue specific insulin resistance to clarify the contribution of different 
organs in the obese subjects following LCD intervention.
In this report, we acquired and analyzed multi-omics datasets from the Diet, Obesity and Genes (DiOGenes) 
study, one of the largest weight maintenance intervention of its kind17. We studied differences between subjects 
previously characterized as glycemic responders and non-responders16. We further investigated their molecular 
and physiological differences both at baseline and during weight loss intervention.
Material/Subjects and Methods
Study design. DiOGenes was a multicenter, randomized controlled dietary intervention study, involving 
eight European countries17,18 (ClinicalTrials.gov number, NCT00390637). The study has been described in detail 
previously16,18 and a CONSORT diagram of the clinical intervention is presented in Fig. 1A. Briefly, 938 over-
weight/obese, non-diabetic, adults (Body Mass Index (BMI) between 27 and 45 kg/m2, blood fasting glucose 
below 6.1 mmol/L) underwent an 8-week weight-loss phase using a complete meal replacement low calorie diet 
(LCD). The LCD provided 800 kcal/day (Modifast, Nutrition et Santé France). Among the 781 participants who 
completed the LCD, 773 achieved >8% weight loss and were randomized to a 26-week weight maintenance diet. 
A total of 548 subjects completed the Weight Maintenance Diet (WMD), among which 375 (~70%) had available 
qc-ed plasma samples at all intervention time-points: baseline (Clinical Intervention Day 1, CID1), after 8-week 
of LCD (CID2) and after 6-month of weight maintenance (CID3).
ethics. Local ethics committees approved the study, each patient provided written informed consent and the 
study was carried out in accordance with the principles of the Declaration of Helsinki. Committees included (1) 
Medical ethical commission from Maastricht University, NL (2) Copenhagen ethical research commission, DK 
(3) Bedfordshire local Research Ethics Committee, Luton and Dunstable Hospital NHS Trust, UK (4) Ethics 
Figure 1. Flowchart for DiOGenes clinical intervention and omics analyses. (A) Clinical intervention with the 
number of participants entering the different phases as well as drop-outs are indicated. (B) Stratification into 
responders/non-responders (C) overview of omics datasets (all data available before and after LCD) (D) weight 
and glycemic characteristics at baseline and upon LCD for responders and non-responders. Abbreviations: CID, 
Clinical Intervention Day; LCD, low-caloric diet; QC: Quality Control; scAT: sub-cutaneous Adipose Tissue 
biopsies; WMD, Weight Maintenance Diets.
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Committee of the Faculty Hospital, Prague University, CZ (5) Ethical Commission by NMTI, Sofia, BG (6) Ethical 
Commission University Potsdam, D (7) Ethical Commission Medical University, Navarra, SP (8) Scientific 
council Heraklion general university hospital, Heraklion, GR and (9) Commission Cantonale d’ éthique de la 
recherche sur l’ être humain, Canton de Vaud, CH.
clinical variables. The following clinical variables were included in the analysis: body mass index (BMI), 
weight, body fat from bio-impedance and waist circumference. Several glycemic control measures were analyzed: 
fasting glucose/insulin; HOMA-IR (glucose (mmol/L) x insulin (mmol/L)/22.5); and Matsuda index, a measure 
of insulin-sensitivity derived from 2-hours oral glucose tolerance tests19. Total lipid levels (cholesterol, TAG, HDL 
and derived-LDL using the Friedwald formula) as well as total free fatty acid (FFA) were analyzed with blood 
biochemistry.
The Visceral Adiposity Index (VAI), a robust index of visceral fat, was derived using the formula proposed by 
Amato et al.20. This index is gender-specific and incorporates the following variables: BMI, waist circumference, 
total TAG and HDL-cholesterol. In this study, it was benchmarked against the Android-gynoid percent fat ratio 
as computed from dual-energy X-ray absorptiometry (DEXA) data available for 80 DiOGenes subjects from 
Denmark.
Additional indices pertaining to tissue-specific insulin-resistance (IR) were derived. This included the 
adipose-tissue IR (adipoIR21); the muscle insulin sensitivity and hepatic-IR indices22 (MISI and HIRI, respec-
tively). AdipoIR corresponds plasma FFA x insulin levels. MISI is derived as the rate of decay of glucose concen-
tration from its peak value to its nadir during Oral Glucose Tolerance Test (OGTT) divided by the mean insulin 
levels. HIRI is derived as the product of total area under curve (AUC) for glucose and insulin during the first 
30 min of the (OGTT).
transcriptomics analysis. Abdominal subcutaneous adipose tissue (AT) biopsies were obtained by needle 
aspiration under local anesthesia after an overnight fast at baseline, at the end of LCD and at the end of weight 
maintenance. Biopsy samples were stored at −80 °C until total RNA extraction. Gene expression at baseline and 
upon LCD was quantified using 100-nt long paired-end RNA sequencing with an Illumina HiSeq 2000. This 
dataset has been previously described9 and data are available from the Gene Expression Omnibus under accession 
GSE95640.
High throughput quantitative real-time PCR (qPCR) was performed as previously described9,23 for specific 
lipogenesis genes (FADS1/2, ELOVL5, FASN and SCD) and leptin (LEP) and at all three intervention timepoints.
plasma omics analysis. Blood samples were taken after an overnight fasting period at baseline and upon 
completion of the LCD and WMD interventions. Figure 1C displays an overview of all omics analyses that were 
conducted in this study.
Lipidomics. LC-MS data generation has been described previously16,24. In total, 125 intact lipids including tria-
cylglycerides, phosphocholines, sphingomyelins, cholesterol-esters, cholesterols and diacylglycerides were meas-
ured at all three intervention timepoints.
Metabolomics. Metabolomics data generation (1H NMR) was also described previously24,25 and quantified 18 
low-weight metabolites related with obesity and insulin-sensitivity. Candidate mechanistic analyses focus on 
plasma ketone bodies (acetoacetate (AcAc) and beta hydroxy-isobutyrate (βHB)) quantified at all three interven-
tion timepoints. Integrative analyses (predictive models) were pursued using all 18 metabolites.
Proteomics. Protein levels were measured using a multiplexed aptamer-based proteomic technology developed 
by SomaLogic Inc (Boulder, CO). This approach uses fluorescently labeled poly-nucleotide aptamers that rec-
ognize specific protein epitopes, similar to protein antibodies quantified using relative fluorescence on microar-
rays26,27. In total, 1,129 plasma proteins were measured, both at baseline and upon LCD. Proteomics data are 
available from the Open Science Framework at this URL https://osf.io/s4v8t/?view_only=90637f2941e14ec986
e5888491fbdbbb.
Quantification and statistical analysis. Lipid signature definition. The lipid signature was available 
from previous work16 and was computed using Principal Component Analyses (PCA) of the log2 fold-change 
for 79 lipids differentially expressed during LCD. The lipid signature was defined as Principal Component 1 
(PC1). This continuous variable could be further dichotomized into responders (subjects with PC1 ≥ 0) and 
non-responders (subjects with PC1 < 0).
Association between lipid signature and clinical variables. Association with clinical variables was tested using 
linear mixed-effect models. The lipid signature (PC1), gender and age were modeled as fixed effects; center was 
modeled as a random effect. Analyses of a clinical endpoints at CID2 (LCD) or CID3 (weight maintenance) were 
adjusted for baseline levels at CID1. P-values were adjusted for multiple testing with the Benjamini-Hochberg 
procedure28. For visualization purpose, results are shown per group (responders/non-responders) and as 
time-series with the mean and its 95% confidence interval at a given CID. In these plots, ANOVA was used 
to compare differences between responders and non-responders at each CID; and adjust for gender, age and 
center. Comparisons between baseline parameters (BMI and Matsuda index) stratified by gender and responder/
non-responder groups were made using ANOVA, followed with a Tukey Honest Significant Test for pairwise 
comparisons.
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Pathway analyses. Enrichment analyses were performed using the KEGG29,30, REACTOME31 and PANTHER32 
databases. Analyses were performed using a Fisher’s exact test. For Somalogic (proteomics) analyses, a back-
ground correction was implemented (by considering the universe as the 1129 proteins assayed on the array). 
Multiple testing adjustments were performed with resampling procedures (Monte-Carlo simulations). 
Significance levels were set at adjusted alpha 5%.
Gene expression analyses. Association between lipid signature and gene expression levels was tested as follows. 
For qPCR, linear mixed effect models were used (as for the analysis with clinical variables). For RNA-seq, due to 
the non-normality of the data, non-parametric approaches were used (ranksum test). Adjustment for multiple 
testing was performed using Benjamini-Hochberg correction.
All analyses were performed using R (v3.3.2)33.
Biochemical pathway analysis. In-silico biochemical pathway analyses were pursued to analyze connections 
between fatty acids involved in the TAG signature including (α-Linolenic Acid, Linoleic Acid, Stearic Acid, 
Palmitic Acid, Arachidonic Acid, Palmitoleic Acid and Oleic Acid) and Acetyl-CoA (as a key connection to keto-
metabolism). Objectives of this analysis were to identify the metabolic intermediates and the metabolic biotrans-
formation routes potentially connecting the free fatty acids to ketometabolism. Methodologically, we used the 
KEGG database34 and specifically the PathComp methodology35 to identify the routes between the compounds of 
interest. We limited our search of paths to a maximum length of 10. Network analysis and visualization of paths 
and interconnectivities were performed using custom MATLAB (Mathwork Inc.) scripts and edited using yEd 
(yWorks GmbH).
Predictive models. Data were split into training and testing datasets. The training set included subjects from 
the two leading DiOGenes intervention centers (Denmark and the Netherlands) and the testing set included 
all remaining six centers. During weight maintenance, the two leading centers provided food freely to the 
participants17,18. We thus assumed that compliance to the randomized diet was higher for these two centers. 
Nevertheless, we also retrained models using a training set composed from a random subset over all eight centers.
Different types of predictive models were tested: Elastic Nets36, Random Forests37 and Gradient Boosting 
Machine(GBM)38. These models were fitted on the training set, using internal cross-validation (10-fold CV, 
repeated 5 times).
For elastic nets, model optimization was performed using the following grid of parameters: Alphas: 0 (ridge), 
0.25, 0.50, 0.75, 1 (lasso) and lambdas: from 0.001 to 0.20, by equally spaced up to n = 40. For Random Forest, 
optimization was carried by testing different number of trees (up to 500). For GBM, optimization was carried 
over a grid with the following parameters: number of trees: 50, 500; max iteration depth 1.3; shrinkage 0.001, 
0.005 and 0.01 and minimal terminal node size: 5, 10. The performance of a model was evaluated using Receiving 
Operating Curves (ROC curves). Models were tested using different set of features. The clinical model was based 
on 19 features (gender, weight, BMI, amount of fat mass, percentage of fat mass, waist circumference, VAI index, 
HOMA-IR, fasting glucose and insulin, Matsuda index, total cholesterol, HDL, LDL, triglycerides, fatty acids, 
adipose-IR, liver-IR and muscle-IR). Two sets of omics models were tested, the first set included previous clinical 
parameters and all features from lipidomics, metabolomics, and proteomics. This resulted in 1246 features. The 
second omics model, corresponded to a subset of the first model (with only 93 features), and was obtained by 
selecting features displaying marginal association with the responder status (Kruskal-Wallis analyses using only 
data from the training set, and with a very liberal significance level at alpha 30%) and also by discarding features 
that displayed either near-zero variance, were obtained through linear combinations from other features, or were 
highly correlated with another feature (Pearson R2 > 95%).
All analyses were performed using the caret R package39. Data were mean-centered and scaled to unit-variance 
by the caret preprocess function.
Evaluation of the ROC AUCs and their confidence intervals was performed using the pROC R package40. 
Comparison of any two ROC curves was made using the Delong’s test, as implemented in the roc.test function 
from the pROC package.
Results
Phenotyping and characterization of the responders and non-responders. Our study focuses on 
375 overweight/obese, non-diabetic subjects from the DiOGenes cohort (with mean age 42 years old, and with 
66% of women). These subjects followed first a weight loss intervention followed with a 6-month weight mainte-
nance randomized intervention (Fig. 1A). By design, the weight maintenance intervention was only performed 
in subjects that had lost >8% of body weight.
Using a previously identify signature16 reflecting changes in plasma lipid composition during LCD, we could 
stratify subjects into two groups (responders or non-responders) with respect to glycemic improvements 6-month 
after LCD completion16 (Fig. 1B). This past study reported the lipid signature as a surrogate for both weight and 
glycemic improvements but did not aim to study the underlying physiology and molecular differences. In the 
present study, we perform a more comprehensive omics characterization of these two groups. Namely, we took 
advantages of other DiOGenes omics datasets, that encompassed transcriptomics, proteomics and metabolomics 
profiles (Fig. 1C). We also sought to study possible gender-specific differences and to pursue a deeper investiga-
tion from the lipid signature.
Previous analyses of clinical and physiological parameters had shown that these two groups (responders 
and non-responders) are comparable at baseline in term of weight and insulin sensitivity (Fig. 1D). Upon LCD, 
both groups had achieved significant weight loss (>8% initial body weight); yet the responder group had signif-
icantly higher weight loss (mean difference +2% improved weight loss with 95% CI (0.97, 2.34), two-sided t-test 
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p = 2.58e-6). This same group also displayed significant improvements in insulin sensitivity (mean change in 
HOMA-IR index: −0.92 with 95% CI (−1.17, −0.66), p = 4.3e-11). The non-responders displayed no significant 
insulin sensitivity improvements (−0.25 with 95% CI (−0.64, 0.14), p = 0.21; Fig. 1D).
Gender-specific characteristics. We observed that 61% of the women were non-responders while this 
proportion was about 40% in men (odds ratio=2.48 with 95% CI (1.55, 3.90), Fisher’s exact test p = 5.3e-5). 
Pairwise comparisons between gender and responder status (Fig. 2 and Supplemental Table 1) showed that, inde-
pendently of their responder status, men and women had similar baseline BMI, but that women were more 
insulin sensitive (higher Matsuda index) compared to men, suggesting less room for improvement during LCD. 
Indeed, upon LCD, responder men had significantly higher improvements of Matsuda index compared to their 
women counterpart (p = 2.5e-6, Fig. 2). With subsequent analysis, we sought to investigate the clinical and molec-
ular differences between responders and non-responders, both globally (with gender-adjusted analyses) and in a 
gender-specific manner (gender-stratified analyses).
Lipidomics profile characterization. The lipid signature is mostly composed of TAGs, which is consistent 
with results from total triglyceride levels showing that responders had significantly higher baseline levels than 
non-responders (p = 3.3e-6) and displayed significant down-regulation during LCD while non-responders did 
not display any significant changes during intervention (Supplemental Fig. 1). Consistent effects were found 
between men and women, with responders having higher baseline levels and stronger down-regulation during 
LCD and upon weight maintenance (Supplemental Table 2). Examination of individual lipids from the signature 
also confirmed these observations (Supplemental Fig. 2) and highlighted a shift in concentrations from TAGs of 
lower carbon number (42–54) and double bond (0–4).
Figure 2. Boxplot of baseline BMI and Matsuda, and improvements during LCD. (A) Baseline BMI (B) 
baseline Matsuda index (C) percentage of BMI changes during LCD, relative to baseline (D) percentage of 
Matsuda index changes during LCD, relative to baseline. Groups are defined according to responder/non-
responder status and gender (M/F). The displayed P-values were obtained from a Tukey Honest Significant Test 
(see Methods) and are adjusted for multiple testing. P-values greater than 5% are not shown.
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Characterization based on transcriptomics profile. To further investigate the role of adipose tissue 
in differences observed between responders and non-responders, we used RNAseq data for 350 genes previ-
ously documented as differentially expressed during LCD and linked with weight loss clinical outcomes9. Within 
this list, no gene displayed significant differences in baseline levels between responders and non-responders 
(smallest FDR = 0.44). At FDR < 5%, 15 genes had different evolution during LCD between responders and 
non-responders (Supplementary Table 3). Since such number of genes is not sufficient for pathway analyses, 
we relaxed the FDR cutoff to 10% and used 68 genes. Significant enrichments (FDR < 5%) were found in path-
ways pertaining to PPAR and leptin signaling; TAG and ketone body metabolism and fatty acid elongation 
(Supplementary Table 4). We observed that 15 genes (ACADL, ACSL1, AKR1C2, ANGPT1, APBB1IP, CYP46A1, 
ELOVL5, GRIN2B, KLB, LEP, ME1, MECR, PTPLB, SCD) were driving these enrichments; with ELOVL5 and SCD 
involved in all fatty acid pathways.
Using targeted qPCR, we further investigated the expression of lipogenic genes including FASN, SCD, 
FADS1, FADS2 and ELOVL5 as well as LEP in adipose tissue biopsies. At baseline, both groups had comparable 
expression levels (nominal p > 5%, Supplemental Fig. 3). Following LCD, all these lipogenic genes distinguished 
responders from non-responders; with responders having significantly stronger down-regulation, including in 
gender-stratified analyses (FDR < 5%, Supplemental Table 5). The lipogenic genes all reached their initial levels 
during the weight maintenance phase. Leptin remained significantly down-regulated at study termination com-
pared to baseline (p = 2.71e-6) and this down-regulation was significantly stronger in responders compared to 
non-responders (p = 0.0048).
Characterization based on indices of visceral fat and tissue-specific insulin resistance. To fur-
ther investigate the role and contribution of adipose tissue, we calculated visceral adiposity index (VAI) using 
BMI, waist circumference, total triglycerides and HDL as a surrogate marker of adipose tissue dysfunction as 
described previously20. While the groups were comparable, at baseline, in term of central obesity (as assessed 
with weight and BMI), they significantly differed in their Visceral Adiposity index (VAI), with responders hav-
ing significantly higher baseline indices (p = 9.39e-5). Longitudinal analyses of the VAI showed that respond-
ers achieved significant reduction of visceral fat upon LCD and were able to maintain such reduction (Fig. 3). 
Conversely, non-responders did not show any significant changes in visceral fat content both upon LCD and 
weight maintenance. Gender-stratified analyses confirmed all these observations (Supplemental Table 2). Based 
on a subset of the DiOGenes cohort (N = 80 Danish subjects) and with ANOVA analyses adjusted for gender, we 
observed significant differences in DXA data (android-gynoid percent fat ratio at baseline) between responders 
and non-responders (p = 4.87e-7). Stratified analyses by gender reached the same conclusions (with p = 0.001 and 
Figure 3. Evolution of visceral fat, tissue-specific IR indices, free fatty acid and ketone bodies during 
intervention. Data are shown as mean +/− 95% CI per group (responders/non-responders). P-values compare 
the difference between responders and non-responders at a given CID. Those p-values are adjusted for gender, 
age and center. P-values greater than 5% are not shown.
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0.016 respectively for the male- and female-stratified analyses). Altogether these results show that responders had 
more visceral fat than non-responders, independently of gender.
Transcriptomics profiles, VAI and DXA indicated to the contribution of adipose tissue to the observed 
stratification and to glycemic outcome. Thus, we sought to further investigate the contribution of other organs 
by evaluating established indices of tissue-specific insulin resistance (adipose tissue, liver, and muscle; see 
Methods). At baseline, the two groups were comparable for all three indices (Supplemental Table 1), which is 
consistent with their overall insulin sensitivity (as assessed with fasting glucose/insulin levels; HOMA-IR and 
Matsuda index). Significant differences between groups were observed in changes in adipoIR index upon LCD 
(p = 0.008) and weight maintenance (p = 0.02). Specifically, responders displayed significantly better improve-
ments than non-responders (Fig. 3). Significant differences were also observed in changes in hepatic insulin 
resistance (HIRI), both upon LCD (p = 0.002) and weight maintenance (p = 1.6e-4, Fig. 3) and were confirmed 
with gender-stratified analyses (Supplemental Table 2). No significant differences, independently of gender, were 
observed for improvements in muscle-specific IR (MISI), neither upon LCD or weight maintenance.
Finally, we compared plasma total levels of free fatty acids (FFA). No significant differences were 
observed at baseline. Overall, subjects significantly reduced their FFA levels at study termination (mean 
change = −83.32 mmol/L with 95% CI (−120.33, −46.30), p = 1.38e-5). During LCD, responders displayed sig-
nificant higher increase in FFA than non-responders (p = 1.5e-4, see Fig. 3) but had comparable levels upon 
weight maintenance (p = 0.65). Gender-stratified analyses showed significant differences in women (p = 0.002) 
but no differences in men (p = 0.19). Since this study included twice more women than men, this may possibly 
due to a lack of statistical power.
Alteration in ketone bodies. Metabolomics analysis revealed significant difference in level of plasma 
ketone bodies including AcAc and βHB between responders and non-responders at the baseline as well as during 
intervention; with consistent effects in males and females (Supplemental Table 2). Specifically, responders had 
significantly lower baseline levels and higher increase in ketone bodies during LCD, yielding to higher levels at 
LCD termination (Fig. 3). During weight maintenance, both groups displayed reduction in ketone bodies but at 
study termination both groups had comparable levels (p > 0.1).
Biochemical connections between fatty acids and Acetyl-coA. Given the differences between the 
responders and the non-responders in terms of free fatty acids, TAGs and ketone bodies, we subsequently used 
biochemical pathway analysis (details in materials and methods) to identify the mechanistic linkages between 
fatty acids (α-Linolenic Acid, Linoleic Acid, Stearic Acid, Palmitic Acid, Arachidonic Acid, Palmitoleic Acid 
and Oleic Acid), that were enriched in triglycerides, and Acetyl-CoA (as a key component of ketometabolism). 
Using this approach, with a maximum route length of 10, we identified several routes connecting α-Linolenic 
Acid (36 routes), Linoleic Acid (36 routes), Stearic Acid (1 route), Palmitic Acid (5 routes) and Arachidonic 
Acid (36 routes) to Acetyl-CoA (Fig. 4A). However, no feasible mechanistic links were identified for connecting 
Palmitoleic Acid and Oleic Acid to Acetyl-CoA.
All the routes with the details of the intermediate metabolites for these connections are depicted in Fig. 4B. 
Results of this analysis indicate that the shortest route to impact ketometabolism via Acetyl-CoA is by Palmitic 
Acid (5 steps, Palmitic acid - Palmitoyl-CoA - (2E)-Hexadecenoyl-CoA - (S)–3-Hydroxyhexadecenoyl-CoA 
– 3-Oxopalmitoyl-CoA – Acetyl-CoA). Besides the direct route, Palmitic acid can also alter Acetyl-CoA lev-
els via biochemical transformation routes involving Ceramides and Phosphatidylethanolamines (steps >10, 
Supplemental Fig. 4). Similarly, Stearic Acid can directly alter Acetyl-CoA levels (9 steps) and via routes involv-
ing Palmitic Acid and Ceramides. α-Linolenic Acid, Linoleic Acid and Arachidonic Acid were all predicted to 
impact Acetyl-CoA levels via Phosphatidylcholines. The predicted biochemical transformation routes involved 
lipid classes like Phosphatidylserine (PS), Phosphatidylethanolamine (PE), Lysophosphatidylethanolamine 
(LPE), Phosphatidic acid (PA), Lysophosphatidic acid (LPA), Monoacylglycerol (MAG), Diacylglycerol (DAG), 
Triacylglycerol (TAG) and Fatty acids (FA) (Fig. 4C). Based on biochemical transformations, TAG, LPA, PA, PE 
and LPE could all alter Acetyl-CoA levels and result in alteration in ketone bodies. The overall biotransformation 
space (Fig. 4C), connecting FFAs and Acetyl-CoA allows us to comprehend the aforementioned observations of 
significant increase in FFAs and ketometabolism in responders and reduction in FFAs as well as the accumulation 
of specific TAGs with lower carbon number (42–54) and double bond (0–4) in Non-Responders.
Characterization based on proteomics revealed alteration in ApoE. We took advantages of a large 
proteomics dataset (1,129 proteins) quantified from fasting plasma samples at baseline and after LCD41. We first 
assessed whether differences between the two groups could be observed in their baseline protein levels. Following 
adjustment for multiple-testing (FDR < 5%), four somamers (probes) had significant differences in baseline lev-
els between responders and non-responders. All these somamers pertained to the ApoE protein (Supplemental 
Table 6). We observed that responders had higher baseline ApoE protein levels compared to non-responders 
(Fig. 5). During LCD, responders had significant down-regulation in ApoE levels while non-responders displayed 
no significant changes.
We evaluated changes in protein levels during LCD and whether these changes associated with the lipid sig-
nature. In total, 111 somamers (including the four ApoE somamers), pertaining to 106 unique proteins distin-
guished responders from non-responders (Supplemental Table 7). Similar APOE effects were seen in males and 
females (Supplemental Table 2), both for baseline levels and changes during LCD.
Subsequent pathway analyses of these 106 proteins showed significant enrichment in the 22 pathways defini-
tions (Supplemental Table 8). A processed network summary is shown in Fig. 6 and highlights that these enrich-
ments are confined to few specific biological processes: coagulation and complement factors, insulin signaling, 
glycosaminoglycan, lysosome, and lipoprotein metabolism.
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integrative analyses to predict responder’s status using baseline information. Finally, we aimed 
to define predictive model, solely based on baseline parameters that would enable to predict the responder/
non-responder status, prior to any clinical intervention. Whilst most clinical parameters did not display strong 
separation between the two groups, there were still a few such as triglyceride levels, gender, visceral adiposity 
index that showed significant differences; and additional parameters (e.g. cholesterol, BMI) with only marginal 
association (as presented previously). We hypothesized that perhaps the combination from all easily accessible 
clinical parameters may yield some level of prediction. And indeed, using models based on baseline anthropo-
metric parameters, total lipid levels, insulin sensitivity measures (including tissue-specific), as well as gender 
and age,. Some modest performance was achieved (on testing set, ROC AUC = 61%, with 95% CI [51%, 71%]) 
However, this performance was not sufficient for prediction in a clinical setting (with the lower confidence inter-
val very close to 50%, indicating close to random prediction). Analysis using different types of models (elastic 
Figure 4. Biochemical pathway analysis for α-Linolenic Acid, Linoleic Acid, Stearic Acid, Palmitic Acid, 
Arachidonic Acid, Palmitoleic Acid and Oleic Acid to Acetyl-CoA. (A) Number of paths for connecting each 
compound to Acetyl-CoA. (B) Enumeration of the paths (steps <= 10). (C) Overview of the key components 
identified to play a key role in connecting the lipids to Acetyl-CoA.
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Figure 5. Evolution of somamers pertaining to ApoE during LCD. Data are shown as mean +/− 95% CI per 
group (responders/non-responders). P-values compare the difference between responders and non-responders 
at a given CID. Those p-values are adjusted for gender, age and center. P-values greater than 5% are not shown. 
Values on the Y axis correspond to relative fluorescence units, as provided by the Somalogic platform.
Figure 6. Pathways significantly enriched in proteins whose changes in levels during LCD distinguish 
responders from non-responders. This network displays the connections between the constituent proteins 
(shown as ellipses) and the enriched biological pathways (rectangles); the node color indicates whether protein 
levels at LCD termination (CID2) are more pronounced in non-responders (yellow edges) or responders (blue).
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nets, random forests and boosting) all yielded to similar performance, further confirming the difficulty to predict 
responders and non-responders solely based on clinical parameters.
In a second step, we aimed to construct predictive models using plasma omics parameters. Adipose tissue tran-
scriptomics is not easily accessible in clinical routine, and thus was not considered in these analyses. This strategy 
yielded better models (see Fig. 7A,B), with the top omics model reaching AUC = 75% with 95% CI [67%, 83%], 
and outperformed significantly the clinical model (Delong’s two-sided pvalue = 0.00075). The top omics model is 
based on a gradient boosting machine, and incorporate 83 distinct features, whose relative importance is displayed 
in Fig. 7C. This plot reveals that the top features pertains mostly to TAGs, several indicators of fat mass, apolipo-
proteins (Apo E, Apo B, Apo D), indicators of insulin sensitivity (both systemic with HOMA-IR and peripheral 
with adipose IR, and lesser contribution from liver and muscle IR). Gender was also retained by the model, but 
only ranked as 77/83; indicating it had only small contribution to predicting the responder/non-responder sta-
tus. Interestingly, tissue-specific indices of insulin resistance (adipose, liver and muscle) all ranked better (i.e. 
were more informative), than HOMA-IR or individual fasting or insulin levels. This highlights the importance of 
tissue-specific indicators for better diagnostic, as opposed to relying on general metabolic indicators.
Our models were trained using the two leading intervention centers (“shop-centers”) and validated with the 
remaining centers (“non-shop”). The rationale was that the shop-centers provided freely food during weight 
Figure 7. Predictive models based on baseline clinical and plasma omics. (A) Receiving Operating Curves 
(ROC) Area Under the Curve (AUC) for each model (3 set of features × 3 type of models). Performance is 
evaluated on the testing set (not used for constructing the models). AUCs and their 95% Confidence Intervals 
are shown. The line at AUC 50% indicates the performance from a random predictor. Models based on clinical 
parameters uses as input 19 features, the full omics model includes 1246 features, while the prefiltered omics 
model is a subset and uses 93 features as input (see Methods for full details). (B) ROC curves (on testing data) 
for the best models from the 3 set of features. The clinical model is based on an elastic net (glmnet), the Omics 
model with all features is a random forest, while the Omics models with prefiltered features is a gradient 
boosting machine. (C) Feature importance plot for the features retained by the gradient boosting machine 
model (constructed using the prefiltered Omics features as input).
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maintenance and thus compliance to the intended randomized diet was possibly higher. Re-analyses using a 
training set based on a random sampling across all centers, and validation with the remaining data yielded models 
with similar performance (Supplemental Fig. 7). This further demonstrated the robustness of our models.
Discussion
We previously stratified subjects according to their glycemic improvements (6-month after LCD completion) 
based on plasma lipid signature16. In this study we aimed to further characterize these two groups using combina-
tion of multi-omics and biochemical pathway modeling which allowed us to get more insights into the underlying 
mechanism and physiological changes that differentiate these two groups.
We observed that women were more likely non-responders than men, yet at baseline, women already dis-
played significantly better insulin sensitivity (both systemic sensitivity as assessed with Matsuda index and 
HOMA-IR, but also tissue-specific as estimated with proxies for the adipose, muscle and liver). Our main anal-
yses were performed using gender as a covariate to maximize the statistical power42. In addition, we repeated 
our analyses using a gender-stratified approach. While the latter approach is considered suboptimal in term of 
statistical power, we could still confirm that the direction of effects for both clinical and omics key parameter was 
consistent between genders (Supplemental Figs. 5–6). This suggests that the higher prevalence of non-responders 
with the women group, is more likely due to a better baseline condition rather than gender-specific response to 
LCD. Providing support to this hypothesis, in obesity studies and also clinical practice, enrolled women are rela-
tively healthier than men in term of glycemic control. Within the PREVIEW study43, currently the largest weight 
loss study (N = 2,500); women have a significantly less pronounced baseline insulin resistance than men (mean 
HOMA-IR = 3.5 +/− 2.2 SD in women vs 4.24 +/− 2.82 in men; p < 0.001), and generally, a lesser Metabolic 
Syndrome score (mean Z-score 2.4 +/− 3.2 SD in women vs. 2.9 +/− 3.3 in men, p < 0.001). Also, in line with 
our observation that women display lesser insulin sensitivity improvements than men, the PREVIEW study 
found that men displayed better improvement of the Metabolic Syndrome status than women (p < 0.001). This 
yields important considerations for clinical practice. First, differences in metabolic improvements between gen-
der may be due to a difference in baseline status; and might not be due, or only partially, to gender-specific differ-
ence in metabolism and physiology. Whilst this seems obvious, such differences are not discussed in the scientific 
literature and are ignored in weight loss management interventions. Future studies investigating gender-specific 
differences should pay attention to such baseline differences.
Interestingly in our study, we found that the directions of changes were consistent between genders, albeit 
smaller in women. This still prompt the needs elucidate the metabolic differences underlying biomarkers predict-
ing responders and non-responders to weight loss intervention.
We observed that the identified lipid signature that distinguished responders from non-responders was due 
to a shift in fatty acid composition in TAG species. That indicates, not only increase in total level of TAGs but 
also alteration in fatty acid biosynthesis. Most of these TAGs have saturated monounsaturated fatty acyl chains, 
indicating de novo lipogenesis (DNL) as a main contributor to these specific changes44. This hypothesis is in 
agreement with studies demonstrating that the DNL pathway is stimulated in hyper-insulinemic obese subjects 
compared to normo-insulinemic obese subjects and associated with high blood TAGs concentrations, possibly 
exacerbating insulin resistance45.
While our study was limited with regards to access to liver or muscle biopsies, we were able to high-
light tissue-specific effects between the two groups. Using both Visceral Adiposity Index and DXA data 
(android-gynoid ratio), we found that responders had higher visceral fat at baseline compared to non-responders. 
Further analyses during LCD and with adjustments for baseline visceral fat levels, show that visceral fat is signif-
icantly reduced only for responders (non-responders do not show any significant changes). These improvements 
in visceral fat are consistent with their significant improvement in insulin sensitivity in responders (compared to 
non-responders). And indeed, further investigation using established indices of tissue-specific insulin resistance 
(adipose tissue, liver, and muscle) confirmed baseline similarity between the two groups; and that responders had 
significant improvements in both adipose and hepatic insulin resistance indices (adipoIR and HIRI, respectively) 
upon LCD. These concomitant visceral fat reduction and glycemic improvements in responders is consistent with 
the expected physiological mechanisms46. It also emphasizes the need in clinical practice to assess both central 
adiposity (using BMI) and visceral fat (using indices such as VAI).
Gene expression analyses from subcutaneous adipose tissue biopsies provided additional evidence for dif-
ference in lipogenesis pathways (both with candidate qPCR approaches and using RNAseq data). Specifically, 
key lipogenic genes (FASN, SCD, FADS1, FADS2 and ELOVL5), as well as LEP provided consistent results with 
regards to their expected response to LCD and their role in improvements of insulin resistance9,47–49. These anal-
yses further confirmed our hypothesis that alteration in lipid metabolism that differentiate responders from 
non-responders is, at least in part, due to the reduction in de novo lipogenesis in the visceral adipose tissue. 
Further investigation is required to elucidate the contribution of de novo lipogenesis in the liver to the alteration 
in lipid metabolism that differentiate responders from non-responders. However, from plasma proteomics, we 
observed a significant difference in the levels of total ApoE, ApoE2, ApoE3 and ApoE4 between responders and 
non-responders which is indicative of alteration in lipoprotein metabolism and shows a contribution of the liver 
to the observed alteration. ApoE is involved in many steps of lipoprotein homeostasis including triglyceride-rich 
VLDL and chylomicron remnants as well as subset of HDL particles50. Previous studies have shown that ApoE 
is not only important for fat accumulation, but is also linked with mechanisms of insulin resistance and the 
development of the metabolic syndrome51–53. ApoE has a wide tissue distribution and function54. While the liver 
is the major source of plasma ApoE, adipose tissue, including adipocytes and macrophages, is also producing a 
significant amount of this apoproteins55. Our proteomics pathway analyses highlighted other proteins involved 
in lipoprotein metabolism (APOA1, BMP1, FABP3 and ANGPTL4) and that are key markers in obesity and 
NAFLD56–58. Given the link between NAFLD, insulin resistance and lipid metabolism, these markers, as well 
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as other adipo- and hepatokines would deserve further investigation in the context of weight loss and glycemic 
improvements following LCD intervention59.
Finally, since ketone bodies in mammals are produced predominantly in the liver from fatty acid oxidation 
and are important component of several important metabolic pathways such as β-oxidation (FAO), the tricarbox-
ylic acid cycle (TCA), gluconeogenesis and de novo lipogenesis (DNL), we sought to assess if the circulating levels 
are differentiated between responders and non-responders. In-silico biochemical pathway analysis, leveraging 
known biochemical transformation routes, further substantiates the possibility that alterations in the identified 
lipid signature related to fatty acid partitioning in triglycerides could result in alterations in keto-metabolism and 
significant changes in circulating ketone bodies. This is also in agreement with changes that we observed with 
apolipoprotein that further confirms the potential contribution of liver in alteration in TAG-rich VLDL secretion.
The availability of both detailed baseline clinical parameters and plasma omics enabled us to construct and 
evaluate predictive models. These analyses demonstrated the need to acquire omics as a model solely based 
on clinical information was not able to achieve good performance (AUC = 61%, with 95% CI [51%, 71%]). By 
contrast, a more sophisticated model, based on 83 features increased significantly the performance (reaching 
AUC = 75%, with 95% CI [67%, 83%]). This model contrasts with our previous work16, whereby the classification 
into responders/non-responders was only possible using the lipid profile evolution during clinical intervention. 
In other previous studies9,24, we developed models applied to predicting improvements from a single clinical 
outcome (either weight loss or glycemic control); while here our work aims to distinguishes two groups that differ 
in multiple endpoints (weight loss, glycemic control, dyslipidemia) suggesting more complex metabolic improve-
ments and thus a much better physiological improvements regarding obesity-related co-morbidities. Our new 
model also contrasts with a recent cross-sectional study60 aiming to predict baseline HOMA-IR, which pertains 
to a relatively easier task than predicting the response to an intervention24. While our proposed model may appear 
relatively complex for implementation in clinical practice, it remains accessible for translational research and 
only rely on plasma omics, without the need for intrusive biopsies or measurements. Additionally, the ranking of 
these baseline predictors, together with our mechanistic characterization of responders/non-responders during 
intervention, constitute a comprehensive knowledge source to better understand the underlying physiology of 
non-responders and responders. Notably, this further stresses the usefulness of tissue-specific indicators of insu-
lin resistance, relative to more general indicator such as HOMA-IR or fasting glucose/insulin levels. This is fully 
consistent with previous work61 on three distinct cohorts demonstrating the relevance of such indices in the space 
of cardiometabolic diseases and would merit further investigation in complex diseases.
In conclusion, our study demonstrates the utility of multi-omics approaches for patient stratification and 
highlights specific biological processes. Our study provides insights into the role of adipose and liver tissues 
in the context of metabolic improvement following low-caloric meal replacement interventions. Altogether the 
specific omics signatures and gender-specific baseline differences are useful to clinicians to better understand 
inter-subject variability. Furthermore, we propose an integrative plasma omics model, that is able to identify 
non-responders both for weight loss and insulin sensitivity improvements prior to any intervention. We are inves-
tigating the lipoprotein metabolism in another clinical study to provide further insights into the role of liver de 
novo lipogenesis and mechanism of actions which would allow us to design a better nutritional intervention for 
the non-responders.
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